The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

Pharmacogenetics and Genomics

Volumn 23, Issue 9, 2013, Pages 487-493

  Roke, Yvette ^a   Van Harten, Peter N ^a,b   Franke, Barbara ^c   Galesloot, Tessel E ^c   Boot, Annemieke M ^d   Buitelaar, Jan K ^d,e,f  

^a GGZ Central Psychiatric Centre   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Karakter Child and Adolescent Psychiatry University Centre   (Netherlands)

^e RADBOUD UNIVERSITY   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

adolescents; genetics; prolactin; risperidone

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; MELATONIN; NEUROLEPTIC AGENT; PALIPERIDONE; PROLACTIN; PSYCHOSTIMULANT AGENT; RISPERIDONE;

ADOLESCENT; ALLELE; AMENORRHEA; ARTICLE; AUTISM; CHILD; DISRUPTIVE BEHAVIOR; DRUG BLOOD LEVEL; FEMALE; GALACTORRHEA; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR GENE; SCHOOL CHILD; SEXUAL DYSFUNCTION; STUDENT T TEST; TREATMENT DURATION;

EID: 84882263418     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283647c33     Document Type: Article

References (46)

1. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009; 48:1143-1154.
2. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-321.
3. Stigler KA, Diener JT, Kohn AE, Erickson CA, Posey DJ, Mc Dougle CJ. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009; 19:265-274.
4. Wink L, Erickson C, McDougle C. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol 2010; 12:529-538.
5. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80:1050-1057.
6. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008; 20:195-201.
7. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69:26-36.
8. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Paredella M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2008; 19:629-635.
9. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28:53-67.
10. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007; 190:129-134.
11. Calarge CA, Zimmerman B, Xie D, Kuperman S, Slechte JA. A crosssectional evaluation of the effect of risperidone and selective serotonine reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 2010; 1:338-347.
12. Roke Y, van Harten P, Buitelaar J, Tenback DE, de Rijke YB, Boot AM. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. Horm Res Paediatr 2012; 77:235-240.
13. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80:1523-1631.
14. Thompson J, Thomas N, Singleton A, Piggot M, Lloyd S, Perry EK. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7:479-484.
15. Jö nsson EG, Nö then MM, Neidt H, Forslund K, Rylander G, Matilla-Evenden M, et al. Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 1999; 40:31-36.
16. Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Ono S, Otani K, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001; 105: 271-274.
17. Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185:147-151.
18. López-Rodr?́guez R, Román M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 2011; 31:555-562.
19. Yasui-Furukori N, Saito M, Tsuchimine S, Nakagami T, Sato Y, Sugawara N, Kaneko S. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1491-1495.
20. Calarge CA, Ellingrod VL, Acion L, Bliziotes MM, Slechte JA. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009; 19:373-382.
21. Sachse C, Brockmö ller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
22. Hendset M, Molden E, Refsum H, Hermann M. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 2009; 29:537-541.
23. Calarge CA, Miller DD. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21:163-169.
24. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60:469-476.
25. Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27:52-57.
26. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27.
27. Roke Y, Harten van PN, Buitelaar JK, Tenback DE, Quekel LG, de Rijke YB, et al. Bone mineral density and body composition in male adolescents with autism spectrum disorders with and without antipsychotic treatment. Eur J Endocrinol 2012; 167:855-863.
28. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003; 2:23-32.
29. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Slechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 273-288.
30. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, et al. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000; 47:316-323.
31. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index measurements in 1996-7 compared with 1980. Arch Dis Child 2000; 82:107-112.
32. Emlinger MW, Kü hnel W, Ranke MB. Reference ranges for serum concentrations of Lutotropin (LH), Follitropin (FSH), Estradiol (E2), Prolactin, Progesterone, Sex Hormone Binding Globuline (SHBG), Dehydroepiandrosterone sulfate (DHEAS), Cortisol and Ferritin in neonates, children and young adults. Clin Chem Lab Med 2002; 40:1151-1160.
33. McKenna T. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol 2009; 71:466-469.
34. Novalbos J, López-Rodr?́guez R, Román M, Gallego-Sand?́n S, Ochoa D, Abad-Santos F. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol 2010; 30:504-511.
35. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, et al. Human brain dopamine receptors in children and aging adults. Synapse 1987; 1:399-404.
36. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharmacokinet 1989; 17:29-67.
37. Knegtering R, Baselmans P. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162:1010-1012.
38. Weizman R, Dick J, Gil-Ad I, Weitz R, Tyano S, Laron Z. Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. Life Sci 1987; 40:2247-2252.
39. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48:648-654.
40. Kuwabara H, McCaul ME,Wand GS, Earley CJ, Allen RP,Weerts EM, et al. Dissociative changes in the Bmax and KD of dopamine D2/D3 receptors with aging observed in functional subdivisions of the striatum: a revisit with an improved data analysis method. J Nucl Med 2012; 53:805-812.
41. Blaicher W, Imhof MH, Gruber DM, Schneeberger C, Sator MO, Huber JC, et al. Endocrinological disorders. Focusing on melatonin's interactions. Gynecol Obstet Invest 1999; 48:179-182.
42. Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia. CNS Drugs 2010; 24:563-574.
43. Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 2006; 24:381-385.
44. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, et al. Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007; 61:545-550.
45. Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 2006; 16:317-326.
46. Roke Y, Buitelaar JK, Boot AM, Tenback D, Harten van PN. Risk of hyperprolactinemia and sexual side effects in boys aged 10-20 years old with autism spectrum disorders or disruptive behavior disorder treated with risperidone. J Child Adolesc Psychopharmacol 2012; 22:432-439.